Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
3495 3489 3431 3441 3239 Last
1985800 3290000 4221200 4488500 11638100 Volume
-0.14% -0.17% -1.66% +0.29% -5.87% Change
Financials
Sales 2021 3 257 B 31 108 M 31 108 M
Net income 2021 153 B 1 462 M 1 462 M
Net Debt 2021 3 815 B 36 433 M 36 433 M
P/E ratio 2021 38,2x
Yield 2021 5,56%
Sales 2022 3 328 B 31 785 M 31 785 M
Net income 2022 438 B 4 180 M 4 180 M
Net Debt 2022 3 241 B 30 957 M 30 957 M
P/E ratio 2022 11,6x
Yield 2022 5,56%
Capitalization 5 064 B 48 420 M 48 363 M
EV / Sales 2021 2,73x
EV / Sales 2022 2,50x
Nbr of Employees 47 495
Free-Float 99,1%
More Financials
Company
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - sale of services. Net sales are distributed geographically as follows: Japan (18%), Asia (5%), the... 
Sector
Pharmaceuticals
Calendar
02/04 | 07:00amErgebnisveröffentlichung
More about the company
Notations Surperformance© of Takeda Pharmaceutical Company Limited
Trading Rating : Investor Rating :
More Ratings
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/30GLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…
10/30TAKEDA PHARMACEUTICAL : FY2020 H1 Results Demonstrate Portfolio Resilience, Conf..
AQ
10/30TAKEDA PHARMACEUTICAL : Notice of the Revised Forecast of Consolidated Financial..
AQ
10/30Takeda Expands COVID-19 Vaccine Supply in Japan through Partnership with Mode..
AQ
10/30Japan stocks fall, post biggest weekly loss in 3 months on virus worries
RE
10/29Japanese shares slump on virus worries, mixed earnings
RE
10/29MORGAN STANLEY : rates CSL as Equal-weight
AQ
10/29UPDATE2 : Takeda to supply 50 mil. coronavirus vaccine doses in Japan in 2021
AQ
10/29UPDATE1 : Takeda to supply 50 mil. coronavirus vaccine doses in Japan in 2021
AQ
10/29URGENT : Takeda to supply 50 mil. coronavirus vaccine doses in Japan in 2021
AQ
10/29Japan's Takeda to import 50 million doses of Moderna's COVID-19 vaccine, rais..
RE
10/29TAKEDA PHARMACEUTICAL : Urgent Headline News
AQ
10/29TAKEDA PHARMACEUTICAL : FY2020 H1 Results Demonstrate Portfolio Resilience; Conf..
BU
10/29TAKEDA PHARMACEUTICAL : FY2020 H1 Results Demonstrate Portfolio Resilience; Conf..
PU
10/29TAKEDA PHARMACEUTICAL COMPANY LIMITE : Notice of the Revised Forecast of Consoli..
EQ
More news
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/29TAKEDA PHARMACEUTICAL : élargit ses réserves de vaccins contre la COVID-19 au Ja..
10/29TAKEDA PHARMACEUTICAL : erweitert Kapazitäten zur COVID-19-Impfstoffversorgung i..
10/29Takeda relève ses objectifs de bénéfices, s'associe avec Moderna sur le Covid..
10/29Tokyo limite les dégâts face à la nouvelle vague de la pandémie
10/28Tokyo ouvre en net repli face à la nouvelle vague de la pandémie
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 428,46 JPY
Last Close Price 3 239,00 JPY
Spread / Highest target 101%
Spread / Average Target 67,6%
Spread / Lowest Target 26,6%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-25.23%48 420
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493